A Randomized, Double-blind, Placebo-controlled, Preliminary Verifying Study About Safety and Efficacy of Maintenance DCVAC/OvCa After First-line Chemotherapy Added to Standard of Care in Patients With Newly Diagnosed FIGO III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
Latest Information Update: 11 Oct 2021
At a glance
- Drugs DCVAC OvCa (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 30 Apr 2021 Status changed from not yet recruiting to recruiting.
- 14 Apr 2021 New trial record
- 13 Apr 2021 Planned End Date changed from 20 Mar 2025 to 20 Apr 2027.